Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103 is registered in ClinicalTrials.gov with NeuroRx, Inc. as lead sponsor.

NCT NCT07227103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Lead sponsor
NeuroRx, Inc.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
March 31, 2028
Enrollment
400 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression, treatment resistant depression (trd)